Colony Group’s AbbVie ABBV Stock Holding History

Colony Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$22.9M	Sell	153,892 -213	-0.1%	-$31.3K	0.34%	74
2023 Q2	$20.8M	Sell	154,105 -5,031	-3%	-$738K	0.29%	91
2023 Q1	$25.4M	Sell	159,136 -10,172	-6%	-$1.56M	0.38%	66
2022 Q4	$27.4M	Buy	169,308 +2,752	+2%	+$422K	0.39%	60
2022 Q3	$22.4M	Sell	166,556 -4,864	-3%	-$698K	0.39%	61
2022 Q2	$26.3M	Buy	171,420 +16,223	+10%	+$2.48M	0.45%	49
2022 Q1	$25.2M	Buy	155,197 +92,995	+150%	+$13.5M	0.38%	62
2021 Q4	$8.42M	Buy	62,202 +29,939	+93%	+$3.54M	0.15%	124
2021 Q3	$3.48M	Sell	32,263 -131	-0.4%	-$15K	0.07%	230
2021 Q2	$3.65M	Sell	32,394 -1,217	-4%	-$137K	0.07%	213
2021 Q1	$3.64M	Buy	33,611 +1,547	+5%	+$165K	0.08%	215
2020 Q4	$3.44M	Sell	32,064 -3,576	-10%	-$344K	0.08%	206
2020 Q3	$3.12M	Buy	35,640 +3,873	+12%	+$365K	0.08%	210
2020 Q2	$3.12M	Buy	31,767 +1,578	+5%	+$139K	0.09%	196
2020 Q1	$2.3M	Buy	30,189 +2,084	+7%	+$178K	0.07%	221
2019 Q4	$2.49M	Buy	28,105 +3,868	+16%	+$321K	0.06%	260
2019 Q3	$1.83M	Sell	24,237 -4,691	-16%	-$322K	0.06%	278
2019 Q2	$2.1M	Buy	28,928 +7,615	+36%	+$599K	0.07%	265
2019 Q1	$1.72M	Buy	21,313 +11,617	+120%	+$950K	0.07%	226
2018 Q4	$894K	Sell	9,696 -144	-1%	-$12.7K	0.04%	272
2018 Q3	$931K	Buy	9,840 +121	+1%	+$11.5K	0.05%	274
2018 Q2	$900K	Buy	9,719 +1	+0%	+$98	0.05%	271
2018 Q1	$920K	Buy	9,718 +5,033	+107%	+$553K	0.05%	262
2017 Q4	$453K	Buy	4,685 +1,205	+35%	+$114K	0.03%	335
2017 Q3	$309K	Sell	3,480 -741	-18%	-$56.4K	0.02%	355
2017 Q2	$306K	Buy	+4,221	New	+$284K	0.02%	335
2017 Q1	–	Sell	-4,483	Closed	-$281K	–	270
2016 Q4	$281K	Buy	4,483 +479	+12%	+$29.2K	0.03%	238
2016 Q3	$253K	Buy	4,004 +768	+24%	+$49.7K	0.03%	229
2016 Q2	$200K	Buy	+3,236	New	+$197K	0.02%	239
2016 Q1	–	Sell	-4,070	Closed	-$241K	–	245
2015 Q4	$241K	Buy	4,070 +1,340	+49%	+$77.2K	0.02%	340
2015 Q3	$149K	Buy	2,730 +15	+0.6%	+$976	0.02%	361
2015 Q2	$182K	Hold	2,715	–	–	0.02%	350
2015 Q1	$159K	Sell	2,715 -35	-1%	-$2.11K	0.02%	326
2014 Q4	$180K	Sell	2,750 -465	-14%	-$29.3K	0.02%	342
2014 Q3	$186K	Buy	3,215 +200	+7%	+$11.1K	0.02%	316
2014 Q2	$170K	Buy	3,015 +450	+18%	+$23.6K	0.02%	219
2014 Q1	$132K	Buy	2,565 +50	+2%	+$2.53K	0.02%	244
2013 Q4	$133K	Buy	+2,515	New	+$124K	0.02%	245

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Colony Group's ABBV Position: Q3 2023 in Review

Colony Group reduced its AbbVie (ABBV) stake by 0.14% in Q3 2023, selling an estimated $31.3K and leaving 153,892 shares worth $22.9M. The position accounts for 0.34% of the portfolio, ranked #74.

Colony Group first reported a position in ABBV in Q4 2013 and has held it in 38 quarters since. The position peaked at $27.4M in Q4 2022. 3,108 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.

Colony Group held 153,892 shares of AbbVie worth $22.9M as of Q3 2023.
Colony Group sold 213 AbbVie shares in Q3 2023, an estimated $31.3K.
AbbVie made up 0.34% of Colony Group's portfolio in Q3 2023, its #74 holding.
Colony Group first reported a position in AbbVie in Q4 2013 and has held it in 38 quarters since.
Colony Group's AbbVie position peaked at $27.4M in Q4 2022.
3,108 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.

Based on Colony Group's 13F filing for Q3 2023, filed 14 Nov 2023.